Literature review of Triple-negative breast cancer metastasis to lungs and its management through Chemotherapy

Abstract:
The present
study is a review of literature that covers an aspect of role of BRCA1 gene
mutation in breast cancer metastasis, risk of recurrence influenced by stage at
initial presentation, the underlying biology of the tumor, time of relapse
after diagnosis of the primary tumor, reasons for metastasis, various
biological markers discovered up till date, discussion of several mathematical
models, with a focus on how they have been used to predict the initiation time
of metastatic growth, and standard choice of treatment best suited for triple
negative breast cancer metastasis.
Breast
cancer starts as a local disease, but it could metastasize to the lymph nodes
and distant organs. As by definition, Metastatic breast cancer, also known as
Advanced or Stage IV breast cancer, is the stage in breast cancer progression
in which malignant cells from the primary tumor successfully create new tumors
in distant organs. According to the
Research studies, women who have BRCA1 mutations are at higher risk for triple
negative breast cancer. The prognosis of women with triple negative breast
cancers (ER-negative, PR-negative and HER2-neu –negative) is poor as compared
to women with other subtypes of breast cancer. TNBC relapses more frequently
than hormone receptor-positive subtypes and is often associated with poor
outcomes.
Patients and
oncologists always have a dilemma on how to cope with this aggressive disease.
For patients, the diagnosis of breast cancer is fearsome; so when they know
additionally that they suffer from TNBC—a subtype with poor outcomes—this
situation is often more stressful. TNBC patients have a unique pattern of
relapse, which occurs mostly in the first 3 years following diagnosis. Although
metastatic breast cancer is not curable, meaningful improvements in survival
have been seen, coincident with the introduction of newer systemic therapies.
Keywords: TNBC (Triple Negative Breast Cancer), Metastasis,
tumor, ER-negative, PR-negative, HER2-neu negative, BRCA1 mutations, Overall
Survival, Lungs, Mathematical Models, Recurrence, Chemokines, Chemotherapy.
References:
[1]. Amorotti,
G.F., Chiodoni, C., & Shen, F. (2014). Suppression of Invasion and
Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic
Inhibition of Slug Activity. Neoplasia, 16(12),
1047–1058. doi: 10.1016/j.neo.2014.10.006.
[2]. Anders,
C.K., & Carey, L.A. (2009). Biology, Metastatic Patterns and treatment of
patients with Triple-Negative Breast Cancer. Clin Breast Cancer, 9(2): S73–S81. doi: 10.3816/CBC.2009.s.008. (PMCID: PMC2919761).
[3]. Anderson, A., Choy, C., & Neman, J., et al.
(2013). Metastatic breast cancer to the brain: A clinical primer for
Translational Investigation. In: Madame
Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; Retrieved
from: http://www.ncbi.nlm.nih.gov/books/NBK154381/
.
[4]. Andy J.
Minn, A.J., Gupta, G.P., & Siegel, P.M. et al. (2005). Genes that mediate
breast cancer metastasis to lung. Nature,
436, 518-524. doi: 10.1038/nature03799.
[5]. Boyle, P.
(2012). Triple-negative breast cancer: epidemiological considerations and
recommendations. Annals of Oncology,
23 (6): vi7–vi12. doi:10.1093/annonc/mds187.
[6]. Breast
cancer. org. Metastatic or Distant Recurrence Symptoms. Retrieved from: http://www.breastcancer.org/symptoms/types/recur_metast/where_recur/metastic
[7]. Chuang,
H.Y., Lee, E., & Liu, Y.T. (2007). Network-based classification of breast
cancer metastasis. Molecular Systems
Biology, 3: 140. doi: 10.1038/msb4100180.
[8]. Clare, S.E.,
Nakhlis, F., Carl, & Panetta, J.C. (2000). Molecular biology of breast
metastasis: The use of mathematical models to determine relapse and to predict
response to chemotherapy in breast cancer. Breast
Cancer Res, 2(6): 430–435. doi:
10.1186/bcr90.
[9]. Deng, C.X.
(2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response
and cancer evolution. Nucleic Acids
Research, 34 (5): 1416-1426.doi: 10.1093/nar/gkl010.
[10]. Dent, R.,
Hanna, W.M., Trudeau, M. (2009).Pattern of metastatic spread in triple negative
breast cancer. Breast Cancer Research and
Treatment, 115(2), 423-428.
[11]. Dent, R.,
Trudeau, M., & Pritchard, K.I., et al. (2007). Triple-negative breast
cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429. doi: 10.1158/1078-0432.CCR-06-3045.
[12]. Dolle,
J.M., et al. (2009). Risk factors for triple negative breast cancer in women
under the age of 45 years. Cancer Epidemiology Biomarkers &
Prevention. American Association for Cancer Research, 18(4), 1157-66.
(PMID: 19336554).
[13]. Fantozzi,
A., & Christofori, G. (2006). Mouse models of breast cancer metastasis. Breast Cancer Research, 8, 212. doi:
10.1186/bcr1530.
[14]. Ford, D.,
Easton, D.F., & Stratton, M., et al. (1998). Genetic heterogeneity and
Penetrance Analysis of the BRCA1 and BRCA2 genes in Breast Cancer families. The American Society of Human Genetics, 62(3),
676–689. doi: 10.1086/301749.
[15]. Gluz, O.,
et al. (2009). Triple negative breast cancer--current status and future
directions. (2009). Annals of Oncology,
20(12), 1913-27. (PMID: 19901010).
[16]. Gupta,
G.P., & Massagué, J. (2006). Cancer Metastasis: Building a Framework. Cell, 127(4), 679–695.
doi:10.1016/j.cell.2006.11.001.
[17]. Gupta,
G.P., Nguyen, D.X., & Chiang, A.C. (2007). Mediators of vascular remodeling
co-opted for sequential steps in lung metastasis. Nature, 446, 765-770. doi: 10.1038/nature05760.
[18]. Hedenfalk,
I., Duggan, D., & Chen, Y., et al. (2001). Gene-expression profiles in
hereditary breast cancer. N Engl J Med,
344, 539-548. doi: 10.1056/NEJM200102223440801.
[19]. Inman, S.
(2014). Eribulin Improves Survival in Metastatic Triple-Negative Breast Cancer.
Retrieved from: http://www.onclive.com/web-exclusives/Eribulin-Improves-Survival-in-HER2-Negative-Metastatic-Breast-Cancer.
[20]. Isakoff,
S.J. (2010).Triple-negative breast cancer: role of specific chemotherapy
agents. Cancer Journal, 16(1), 53-61 (PMID: 20164691).
[21].
Ismail-Khan, R., & Bui, M.M. (2010). A review of triple-negative breast
cancer. Cancer Control, 17(3),
173-176.
[22]. Karsten,
U., & Goletz, S. (2013). What makes cancer stem cell markers different?. Springer Plus, 2, 301. doi:
10.1186/2193-1801-2-301.
[23]. Kassam, F.,
Enright, K., & Dent, R., et al. (2009). Survival outcomes for patients with
metastatic triple-negative breast cancer: implications for clinical practice
and trial design. Clin Breast Cancer,
9(1), 29-33. doi: 10.3816/CBC.2009.n.005.
[24]. Kennecke,
H., Yerushalmi, R., & Woods, R., et al. (2010). Metastatic Behavior of
Breast Cancer Subtypes. American Society
of Clinical Oncology, 28(20), 3271-3277. doi: 10.1200/JCO.2009.25.9820.
[25]. Korsching,
E., Jeffrey, S.S., & Meinerz, W., et al. Basal carcinoma of the breast
revisited: an old entity with new interpretations. Journal of Clinical Pathology, 61(5), 553-60. (PMID: 18326009).
[26]. Maksimenko,
J., Irmejs, A., & Millasevica, M.N., et al. (2014). Prognostic role of
BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett, 7(1), 278–284. doi:
10.3892/ol.2013.1684.
[27]. Marcus,
J.N., Watson, P., & Page, D.L., et al. (1996). Hereditary breast cancer:
Pathobiology, Prognosis and BRCA1 & BRCA2 Gene linkage. Cancer, 15; 77(4), 697-709.
[28]. National
Cancer Institute. A story of discovery: HER2’s Genetic link to Breast Cancer
Spurs Development of New treatments. Retrieved from: http://www.cancer.gov/research/progress/discovery/HER2#.
[29]. Nguyen,
D.X., & Massagué, J. (2007). Genetic determinants of cancer metastasis. Nature Reviews Genetics, 8, 341-352.
doi: 10.1038/nrg2101.
[30]. Peshkin,
B.N., Alabek, M.L., & Isaacs, C. (2010). BRCA1/2 Mutations and Triple
Negative Breast Cancers. Breast Dis,
32. doi: 10.3233/BD-2010-0306. (PMCID:
PMC3870050).
[31]. Pestalozzi,
B.C. (2009). Brain metastasis and subtypes of breast cancer. Annals of Oncology, 20 (5), 803-805.
doi: 10.1093/annonc/mdp246.
[32]. Phuah,
S.Y., Looi, L.M., & Hassan, N., et al. (2012).Triple-Negative Breast Cancer
and PTEN (Phosphate and Tensin Homologue) loss are predictors of BRCA1 Germline
Mutations in women with Early-onset and familial Breast Cancer, but not in
women with isolated late-onset breast cancer. Breast Cancer Research, 14, R142. doi: 10.1186/bcr3347.
[33]. Pogoda, K.,
Niwińska, A., & Murawska, M., et al. (2013). Analysis of pattern, time and
risk factors influencing recurrence in triple-negative breast cancer patients. Medical Oncology, 30, 388. doi:
10.1007/s12032-012-0388-4.
[34]. Rakha,
E.A., Reis-Filho, J.S., & Ellis, I.O. (2008). Basal-like breast cancer: a
critical review. Journal of Clinical
Oncology, 26(15), 2568-81 (PMID: 18487574).
[35]. Rhee, J.,
Han, S.W., & Oh, D.Y., et al. (2008). The clinicopathologic characteristics
and prognostic significance of triple negativity in node-negative breast
cancer. BMC Cancer, 8, 307. doi:
10.1186/1471-2407-8-307 (PMID: 18947390).
[36]. Schott,
F.A., Hayes, D.F., & Vora, S.R. (2015). Systemic treatment of metastatic
breast cancer in women: Chemotherapy. Retrieved from: http://www.uptodate.com/contents/systemic-treatment-of-metastatic-breast-cancer-in-women-chemotherapy
[37]. Scully,
O.J., Bay, B.H., & Yip, G., et al. (2012). Breast cancer metastasis. Cancer Genomics and Proteomics, 9(5),
311-320.
[38]. Seal, M.D.,
& Chia, S.K. (2010). What is the difference between triple negative and
basal breast cancers?. Cancer Journal: The Journal of Principles
& Practice of Oncology, 16(1), 12-6. (PMID: 20164685).
[39]. Sirohi, B.,
Arnedos, M., & Popat. S., et al. (2008).Platinum-based chemotherapy in
triple-negative breast cancer. Annals of
Oncology, 19(11), 1847-52. (PMID: 18567607).
[40]. Smid, M.,
Wang, Y., & Zhang, Yi., et al. (2008). Subtypes of Breast Cancer Show
Preferential Site of Relapse. Cancer
Research, 68, 3108; doi: 10.1158/0008-5472.
[41]. Talmadge,
J.E., & Fidler, I.J. (2010). AACR Centennial Series: The Biology of Cancer
Metastasis: Historical Perspective. Cancer
Res, 70, 5649. doi: 10.1158/0008-5472.CAN-10-1040.
[42]. Tseng,
L.M., Hsu, N.C., & Chen, S.C., et al. (2013). Distant metastasis in
triple-negative breast cancer. Neoplasma,
60(3), 290-4. doi: 10.4149/neo_2013_038. (PMID: 23373998).
[43]. Weigel, B.,
Peterse, J.L., & Veer, L.J.V. (2005). Breast cancer metastasis: markers and
models. Nature Reviews Cancer, 5,
591-602. doi: 10.1038/nrc1670.
[44]. Weill
Cornell Medical College. (2013, January 14). Aggressive breast cancer's
metastatic path revealed. ScienceDaily. Retrieved October 29, 2015 from www.sciencedaily.com/releases/2013/01/130114124930.htm
[45]. Zhang,
X.H.F., Giuliano, M., & Trivedi, M.V., et al. (2013). Metastasis Dormancy
in Estrogen Receptors- Positive Breast Cancer. Clinical Cancer Research, 19, 6389. doi: 10.1158/1078-043.
[46]. Zhou, W.,
et al. (2010). Long-term survival of women with basal-like ductal carcinoma in
situ of the breast: a population-based cohort study. BMC Cancer, 10, 653 (PMID: 21118480).